Literature DB >> 20340055

Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression.

Zahra Mojtahedi1, Bijan Khademi, Seyed Basir Hashemi, Seyed Mohammad Bagher Abtahi, Mohammad Ali Ghasemi, Mohammad Javad Fattahi, Abbas Ghaderi.   

Abstract

Inflammation has been linked to various steps in tumorigenesis. Interleukin (IL)-6 and IL-18 are two inflammatory cytokines whose serum concentrations are elevated in several types of cancer, including head and neck squamous cell carcinoma (HNSCC) in some studies. This study was designed to analyze the serum concentrations of these cytokines in Iranian HNSCC patients. Serum IL-6 and IL-18 concentrations were assayed by ELISA commercial kits in 65 untreated patients and 20 healthy volunteers. Serum IL-6 concentration was significantly increased in patients compared to healthy individuals (p < 0.000). IL-6 concentration increased as the tumor stage progressed, and a significant difference appeared between stage IV vs. stage I/II/III (p = 0.03) disease. Although serum IL-18 concentration was higher in patients than in healthy individuals, the difference was not statistically significant (p = 0.06). Moreover, there was no association between serum IL-18 concentration and tumor stage (p = 0.47). A significant difference was observed in serum IL-18 concentration according to the gender with higher IL-18 concentration in male patients (p = 0.01). In conclusion, serum concentration of IL-6 might correlate with the stage of tumor progression in Iranian HNSCC patients. Further studies with larger numbers of patients are required to exclude the possible minor correlation of serum IL-18 concentration with tumor stage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340055     DOI: 10.1007/s12253-010-9261-y

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

Review 1.  Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu.

Authors:  K Nakanishi; T Yoshimoto; H Tsutsui; H Okamura
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

2.  Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.

Authors:  Frank Riedel; Inka Zaiss; Denise Herzog; Karl Götte; Ramin Naim; Karl Hörmann
Journal:  Anticancer Res       Date:  2005 Jul-Aug       Impact factor: 2.480

3.  Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.

Authors:  A Jebreel; D Mistry; D Loke; G Dunn; V Hough; K Oliver; N Stafford; J Greenman
Journal:  J Laryngol Otol       Date:  2006-08-15       Impact factor: 1.469

Review 4.  Inflammation and cancer: how hot is the link?

Authors:  Bharat B Aggarwal; Shishir Shishodia; Santosh K Sandur; Manoj K Pandey; Gautam Sethi
Journal:  Biochem Pharmacol       Date:  2006-08-04       Impact factor: 5.858

5.  Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Authors:  Z Chen; P S Malhotra; G R Thomas; F G Ondrey; D C Duffey; C W Smith; I Enamorado; N T Yeh; G S Kroog; S Rudy; L McCullagh; S Mousa; M Quezado; L L Herscher; C Van Waes
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

6.  VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer.

Authors:  Ewa Jablonska; Wioletta Puzewska; Zyta Grabowska; Jakub Jablonski; Lukasz Talarek
Journal:  Cytokine       Date:  2005-05-07       Impact factor: 3.861

7.  Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer.

Authors:  Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

8.  Serum interleukin-18 and nitric oxide activity in bladder carcinoma.

Authors:  Neslihan Bukan; Sinan Sözen; Ugur Coskun; Banu Sancak; Nazan Günel; Ibrahim Bozkirli; Cagri Senocak
Journal:  Eur Cytokine Netw       Date:  2003 Jul-Sep       Impact factor: 2.737

9.  Interleukin-18 gene promoter and serum level in women with ovarian cancer.

Authors:  Alamtaj Samsami Dehaghani; Khatere Shahriary; Mohammad Amin Kashef; Sirous Naeimi; Mohammad Javad Fattahi; Zahra Mojtahedi; Abbas Ghaderi
Journal:  Mol Biol Rep       Date:  2009-03-05       Impact factor: 2.316

10.  Expression of IL-18 in patients with head and neck squamous cell carcinoma.

Authors:  Frank Riedel; Sylvie Adam; Peter Feick; Stephan Haas; Karl Götte; Karl Hörmann
Journal:  Int J Mol Med       Date:  2004-02       Impact factor: 4.101

View more
  16 in total

1.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.

Authors:  Sharon R Pine; Leah E Mechanic; Lindsey Enewold; Anil K Chaturvedi; Hormuzd A Katki; Yun-Ling Zheng; Elise D Bowman; Eric A Engels; Neil E Caporaso; Curtis C Harris
Journal:  J Natl Cancer Inst       Date:  2011-06-17       Impact factor: 13.506

2.  IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Authors:  L P Stabile; A M Egloff; M K Gibson; W E Gooding; J Ohr; P Zhou; N J Rothenberger; L Wang; J L Geiger; J T Flaherty; J R Grandis; J E Bauman
Journal:  Oral Oncol       Date:  2017-04-09       Impact factor: 5.337

3.  Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients.

Authors:  Kaito Shibata; Takafumi Naito; Satoshi Hirakawa; Koji Suzuki; Seiji Hosokawa; Hiroyuki Mineta; Junichi Kawakami
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-19       Impact factor: 3.333

4.  Cultivation of Head and Neck Squamous Cell Carcinoma Cells with Wound Fluid Leads to Cisplatin Resistance via Epithelial-Mesenchymal Transition Induction.

Authors:  Till Jasper Meyer; Manuel Stöth; Helena Moratin; Pascal Ickrath; Marietta Herrmann; Norbert Kleinsasser; Rudolf Hagen; Stephan Hackenberg; Agmal Scherzad
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

5.  C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis.

Authors:  Bo Zhou; Jing Liu; Ze-Mu Wang; Tao Xi
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

6.  Circulating Cytokines and Nitric Oxide are Involved in the Inhibition of Neutrophil Migration in Patients with Uterine Cervical Neoplasia.

Authors:  Douglas Côbo Micheli; Paulo Cesar Fernandes; João Celso Garcia Cruvinel; Isabela Destro Nomelini; Eddie Fernando Candido Murta; Beatriz Martins Tavares-Murta
Journal:  Clin Med Insights Oncol       Date:  2012-05-28

7.  Association between Serum Levels of Interleukin-6 and Stage of Laryngeal Cancer.

Authors:  Soheila Nikakhlagh; Nastran Ranjbari; Elaheh Khorami; Nader Saki
Journal:  Iran J Otorhinolaryngol       Date:  2015-05

8.  Evaluation of pretreatment serum interleukin-6 and tumour necrosis factor alpha as a potential biomarker for recurrence in patients with oral squamous cell carcinoma.

Authors:  Ivana Skrinjar; Vlaho Brailo; Danica Vidovic-Juras; Vanja Vucicevic-Boras; Aleksandar Milenovic
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-07-01

9.  Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.

Authors:  Jian Gao; Sen Zhao; Trond S Halstensen
Journal:  Oncol Rep       Date:  2016-04-20       Impact factor: 3.906

10.  Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma.

Authors:  Teppei Jinno; Shintaro Kawano; Yasuyuki Maruse; Ryota Matsubara; Yuichi Goto; Taiki Sakamoto; Yuma Hashiguchi; Naoki Kaneko; Hideaki Tanaka; Ryoji Kitamura; Takeshi Toyoshima; Akiko Jinno; Masafumi Moriyama; Kazunari Oobu; Tamotsu Kiyoshima; Seiji Nakamura
Journal:  Oncol Rep       Date:  2015-03-06       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.